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Background: Extended spectrum ß-lactamases (ESBLs) represent a major group of lactamases responsible for
resistance, mostly produced by gram-negative bacteria, to newer generations of ß-lactam drugs currently being
identified in large numbers worldwide. The present study was undertaken to see the frequency of ESBL producing
Pseudomonas spp. isolated from six hundred clinical specimens (wound, pus, aural, urine, sputum, throat and other
swabs) collected over a period of three years from two tertiary care hospitals in Bangladesh.
Findings: Aerobic bacterial culture was performed on aseptically collected swabs and only growth of Pseudomonas
was considered for further species identification and ESBL production along with serotyping of Pseudomonas
aeruginosa. Antimicrobial susceptibility testing was carried out using the Kirby-Bauer agar diffusion method and
ESBL production was detected on Mueller Hinton agar by double-disk synergy technique using
Amoxicillin-Clavulanic acid with Ceftazidime, Cefotaxime, Ceftriaxone and Aztreonam. Culture yielded 120
Pseudomonas spp. and 82 of them were biochemically characterized for species. Pseudomonas aeruginosa was
found to be the predominant (90.2%) species. Of 82 isolates tested for ESBL, 31 (37.8%) were ESBL positive with 29
(93.5%) as Pseudomonas aeruginosa, the remaining 2 (6.5%) were Stenotrophomonas maltophilia and Ralstonia
pickettii. Antibiogram revealed Imipenem as the most effective drug (93.3%) among all antimicrobials used against
Pseudomonas spp. followed by Aminoglycosides (63.7%).
Conclusion: ESBL producing Pseudomonas spp. was found to be a frequent isolate from two tertiary care hospitals
in Bangladesh, showing limited susceptibility to antimicrobials and decreased susceptibility to Imipenem in
particular, which is a matter of great concern.
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The worldwide emergence of multi-drug resistant bacterial
strains is a growing concern, especially infections caused
by Pseudomonas spp. and P. aeruginosa in particular. P.
aeruginosa is an opportunistic pathogen with innate re-
sistance to many antibiotics and disinfectants including
anti-pseudomonal Penicillins, Ceftazidime, Carbapenems,
Aminoglycosides and Ciprofloxacin [1]. Infections due to
P. aeruginosa are seldom encountered in healthy adults;* Correspondence: drsalamrmc@yahoo.com
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reproduction in any medium, provided the orbut in the last two decades, the organism has become
increasingly recognized as the etiological agent in patients
with impaired immune defenses [2]. Pseudomonads are
more versatile than Enterobacteriaceae in acquiring drug
resistance by various mechanisms. The production of
extended-spectrum beta-lactamases (ESBLs) confers resis-
tance at various levels to expanded spectrum Cephalospo-
rins [3]. These enzymes are encoded by different genes
located on either chromosomes or plasmids [4]. ESBL-
producing bacteria may not be detectable by the routine
disk diffusion susceptibility test, leading to inappropriate
use of antibiotics and treatment failure.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Rate of detection of Pseudomonas spp. and ESBL-
positive strains from clinical specimens
Specimens (n) Pseudomonas spp. n (%) ESBL-positive n (%)
Wound swab (200) 19 (9.5) 5 (26.3)
Pus (110) 20 (18.2) 7 (35)
Aural swab (80) 18 (22.5) 6 (33.3)
Urine (100) 12 (12) 9 (75)
Sputum (50) 8 (16) 2 (25)
Throat swab (50) 4 (8) 2 (50)
Others (10) 1 (10) 0 (0)
Total 82 31 (37.8)
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detection of ESBLs in clinical isolates [5], such as disk
approximation or double disk synergy, modified double
disc test (MDDT), CLSI phenotypic confirmatory me-
thod, E-test ESBL strips, three dimensional test, Vitek
system, etc. While each of these tests has merit, none
are able to detect all of the ESBLs encountered. Disk
approximation or double disk synergy is one of the cu-
rrently available and most widely used techniques for
the detection of ESBLs [6].
Although bacterial resistance to the beta-lactam drugs
and the mechanisms leading to this resistance have be-
come a primary focus for clinicians and researchers, until
recently, only a few studies have been carried out to detect
ESBL bacteria in Bangladesh. Further, routine ESBL
phenotype screening is not yet practiced in Bangladesh.
The present study was conducted with an aim to detect
the prevalence of ESBL-producing Pseudomonas spp. iso-





The study examined 600 swabs including from wounds
(n =200), pus (n =110), urine (n =100), aural (n =80),
sputum (n =50), throat (n =50), umbilicus and conjunctiva
(n =10) taken from patients of different ages and sex
attending at Rajshahi Medical College Hospital (RMCH)
and BIRDEM Hospital, Dhaka, Bangladesh from July 2000
to September 2003. Laboratory works were performed at
the Microbiology laboratory of Rajshahi Medical College,
BIRDEM hospital and the Molecular Biology laboratory
of the Institute of Biological Sciences (IBSc), Rajshahi Uni-
versity. The study was ethically approved by the Ethical
Review Committee of the Institute of Biological Sciences
(IBSc), Rajshahi University and written informed consent
was obtained from patients or a legal guardian in the case
of minors.
Culture and identification of species and serotypes
Following aseptic collection, swabs were routinely inocu-
lated onto Blood and MacConkey agar media. The plates
were incubated overnight aerobically at 37°C and then
checked for bacterial growth. Pseudomonas spp. were
identified by their colony morphology, staining charac-
ters, pigment production, motility and other relevant
biochemical tests as per standard methods of identifica-
tion. Cetrimide agar medium was used as selective
media for subculturing Pseudomonas spp. Isolates were
categorized into different species based on their distinct
biochemical and pigment production characteristics [7]
and serotyping of Pseudomonas aeruginosa was done
using commercially available (Denka Seiken Co. Ltd.,Japan) polyvalent I, II and III group specific antisera
against 14 O antigens.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing of Pseudomonas spp.
was done by the Kirby-Bauer agar diffusion method using
P. aeruginosa ATCC 27853 as the control strain. Commer-
cially available (Hi-Media) antimicrobial disks of Piperaci-
llin (PIP 100 μg), Amikacin (AMI 30 μg), Carbinicillin
(CARB 100 μg), Ceftazidime (CAZ 30 μg), Ceftriaxone
(CRO 30 μg), Cefotaxime (CTX 30 μg), Tetracycline (TET
30 μg), Gentamycin (GEN 10 μg), Ciprofloxacin (CIP 5 μg),
Tobramycin (TOB 10 μg), Imipenem (IMP 10 μg) and
Netilmycin (NET 30 μg) were used on Mueller Hinton agar
(MHA, Hi-Media) to test susceptibility. Zone of inhibition
was recorded as Sensitive or Resistant according to CLSI
guidelines [8].
Detection of ESBL by double disc diffusion synergy method
ESBL production in Pseudomonas spp. was detected by
double disk synergy test (DDST) as described by Jarlier
[9]. Mueller Hinton agar was inoculated with standar-
dized inoculum (corresponding to 0.5 McFarland tube)
using sterile cotton swab. An Augmentin (20 μg Amoxi-
cillin and 10 μg of Clavulanic acid- AMC) disk was
placed in the center of the plate and test disks of 3rd
generation Cephalosporins (Ceftazidime- CAZ 30 μg,
Ceftriaxone-CRO 30 μg, Cefotaxime-CTX 30 μg) and
Aztreonam (ATM 30 μg) disks were placed at 20 mm
distance (center to center) from the Amoxicillin-
Clavulanic acid disk prior to incubation. The plate was
incubated overnight at 35°C. Enhancement of the zone
of inhibition of any one of the four drug disks toward
Amoxicillin-Clavulanic acid suggested the presence of
extended-spectrum beta-lactamases.
Results
Table 1 shows the frequency distribution of Pseudomonas
spp. with the number of ESBL-positive cases. Of 82 strains
of Pseudomonas spp. tested for ESBL, 31 (37.8%) were
found as ESBL-positive with the highest frequency (75%)
Table 2 Pseudomonas species and serotypes of
Pseudomonas aeruginosa with ESBL positivity
Species Number ESBL-positive n (%)




P. fluorescens 2 0
S. multophilia 2 1 (50)
R. pickettii 2 1 (50)
P. alkaligenes 2 0
Total 82 31 (37.8)
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(33.3%) wound (26.3%) and sputum (25%).
Distribution of Pseudomonas species and serotypes of
Pseudomonas aeruginosa with ESBL positive strains are
shown in Table 2. Of 120 Pseudomonas isolates, 82 were
identified at the species level based on their distinct bio-
chemical and pigment production characteristics [7].
Pseudomonas aeruginosa, Pseudomonas fluorescens, Steno-
trophomonas maltophilia, Ralstonia pickettii and Pseudo-
monas alkaligenes were detected at a frequency of 74
(90.2%), 2 (2.45%), 2 (2.45%), 2 (2.45%) and 2 (2.45%)
respectively. Of 74 Pseudomonas aeruginosa isolates, 29
(39.2%) were ESBL positive. Serotyping of Pseudomonas
aeruginosa revealed 25 as A,C,H,I,L (polyvalent group I),
17 as B,J,K,M (polyvalent group II) and 32 as D,E,F,G,N
(polyvalent group III).
Antimicrobial susceptibility pattern revealed that Imipe-
nem was the most effective drug against Pseudomonas
spp. with susceptibility of 93.3%, followed by Tobramycin
(66.7%), Amikacin (63.7%) and Gentamycin (60%). Sus-
ceptibility of Pseudomonas spp. to 3rd generation Cepha-
losporins ranged from 43.3 to 46.7% and Aminoglycosides
had better efficacy than 3rd generation Cephalosporins
(Table 3).
Discussion
ESBL-producing organisms pose unique challenges to
clinical microbiologists, clinicians, infection control pro-
fessionals and scientists engaged in finding new antibac-
terial molecules. ESBL-producing strains are usually
found in those hospitals where antibiotic use is frequent
and the patients are in critical condition. In the present
study, 120 Pseudomonas spp. were isolated from 600
bacterial cultures with Pseudomonas aeruginosa as theTable 3 Antimicrobial susceptibility pattern of Pseudomonas
Antimicrobi
Susceptibility% PIP CARB CAZ CRO CTX
58 43.3 46.7 46.4 43.3most frequent (90.2%) species accounting for 18% of
clinical cases. The prevalence of P. aeruginosa is consis-
tent with the findings of Wiblin (1997), who documen-
ted 16% prevalence for various infections [10].
The rates of ESBL-positive Pseudomonas spp. (37.8%)
and Pseudomonas aeruginosa (39.2%) found in our study
were in accordance with similar studies conducted in
Bangladesh and other South East Asian countries
[3,4,11-13], although low detection rates of 3.7% to 7.7%
were noted in studies conducted by others [14,15]. Infec-
tion patterns, hospital infection control measures and
antibiotic policy are all important considerations for varia-
tion of detection rates in different hospitals. Of note, we
also found two ESBL-negative P. fluorescens species, and a
recent study has shown that these species produce
metallo-beta-lactamase, another very important beta-
lactam inhibitor that can act as a reservoir of multidrug
resistance element that may be transferred to successful P.
aeruginosa clones [16].
The distribution of ESBL-positive Pseudomonas spp. in
different samples and its resistance to 3rd generation
Cephalosporins is comparable to the findings of Aggar-
wal et al. [4]. This resistance is due to the hydrolysis of
the β-lactam ring by the action of β-lactamase enzymes.
Other mechanisms for drug resistance to the β-lactam
group of antibiotics are loss of outer membrane protein,
production of class C AmpC β-lactamases and altered
target sites. ESBL enzymes are inhibited by β-lactamase
inhibitors, particularly Clavulanic acid and Sulbactam.
Hence the use of β-lactam/β-lactamase inhibitor com-
bination therapy may be an alternative to 3rd generation
Cephalosporins, but the effect of this combination varies
depending on the subtype of ESBL present [17].
Imipenem was found to be the most efficacious drug
against Pseudomonas spp. in our study, which is in
accordance with findings of Ullah et al. [13]; however,
notably in our study, Imipenem underperformed compared
to the 100% susceptibility found in ESBL-producing gram-
negative isolates, including P. aeruginosa, in different
studies [13,18]. Decreased susceptibility to Imipenem is a
matter of great concern for treating infections caused by
Pseudomonas aeruginosa and indicates the urgent need
for improved infection control strategies.
Conclusion
ESBL-producing Pseudomonas spp., and P. aeruginosa in
particular, were found to be frequent isolates from two ter-
tiary care hospitals in Bangladesh with limited susceptibilityspp
al drugs
CIP TET AMI GEN TOB NET IMP
40 32.5 63.7 60 66.7 53.3 93.3
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nem is a matter of great concern as it is the drug of choice
in the treatment of Pseudomonad infection.
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